​

Funding Round

Series B - ADARx Pharmaceuticals

Series B - ADARx Pharmaceuticals

Investment Firm

Overview

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.

Announced Date

Jan 20, 2023

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Ascenta Capital

Ascenta Capital

Ascenta Capital is a early_stage_venture and late_stage_venture and private_equity firm.

Participant Investors

4

Investor Name
Participant InvestorAscenta Capital
Participant InvestorOrbiMed
Participant InvestorSR One
Participant InvestorLilly Asia Ventures

Round Details and Background

ADARx Pharmaceuticals raised $46000000 on 2023-01-20 in Series B

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Nov 12, 2020
Venture Round - ADARx Pharmaceuticals
-6.0M
Sep 08, 2021
Series B - ADARx Pharmaceuticals
4-75.0M
Jan 20, 2023
Series B - ADARx Pharmaceuticals
5-46.0M
Aug 09, 2023
Series C - ADARx Pharmaceuticals
16-200.0M

Recent Activity

There is no recent news or activity for this profile.